sample with an effective amount of a compound of any one of claims 1-36, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition of claim 37 or 38.

- 50. The method of any one of claims 39-48 further comprising administering to the subject a therapeutically effective amount of an additional pharmaceutical agent in combination with the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or the pharmaceutical composition.
- 51. The method of claim 49 further comprising contacting the biological sample with an additional pharmaceutical agent in combination with the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or the pharmaceutical composition.
- 52. The method of claim 49 or 51, wherein the biological sample is a cell or tissue.
- 53. The method of claim 50 or 51, wherein the additional pharmaceutical agent is an anti-proliferative agent.
- **54.** Use of a compound to treat and/or prevent a disease in a subject in need thereof, the use comprising administering to the subject a therapeutically effective amount of a

compound of any one of claims 1-36, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition of claim 37 or 38.

55. A compound of any one of claims **1-36**, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition of claim **37** or **38**, for use in treating a disease in a subject in need thereof.

56. A kit comprising:

a compound of any one of claims 1-36, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition of claim 37 or 38; and

instructions for administering to a subject or contacting a biological sample with the compound, or the pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or the pharmaceutical composition.

* * * * *